Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. (PubMed, J Pharmacol Exp Ther) - Jul 17, 2025 - P1 | "SIGNIFICANCE STATEMENT: KZR-834 and KZR-261 are novel Sec61 inhibitors with the ability to block multiple Sec61 client proteins, leading to well-tolerated efficacy in in vivo cancer models. This represents a novel mechanism for blocking expression of oncogenic factors, including those not amenable to targeting through conventional methods."
IO biomarker • Journal • Preclinical • Oncology • SEC61G
|
|
Aaron Kempema; Ajia Sugahara; Beatriz Millare; Brian Tuch; Chengguo Dong; Christopher J Kirk; Cristina Delgado-Martin; Dale Tranter; David Bade; Dustin McMinn; Eric Lowe; Eunyong Park; Giovanna Scapin; Henry W B Johnson; Jack Taunton; Janet L Anderl; Jennifer A Whang; Jing Jiang; Jinhai Wang; Laurie Wang; Neel K Anand; Nicole Poweleit; Patricia Zuno-Mitchell; Phil McGilvray; R Andrea Fan; Shahid Rehan; Tony Muchamuel; Ville O Paavilainen; Ying Fang; Yu Qian
|